| Literature DB >> 21596854 |
Alan M Hanash1, Lucy W Kappel, Nury L Yim, Rebecca A Nejat, Gabrielle L Goldberg, Odette M Smith, Uttam K Rao, Lindsay Dykstra, Il-Kang Na, Amanda M Holland, Jarrod A Dudakov, Chen Liu, George F Murphy, Warren J Leonard, Glenn Heller, Marcel R M van den Brink.
Abstract
IL-21 is a proinflammatory cytokine produced by Th17 cells. Abrogation of IL-21 signaling has recently been shown to reduce GVHD while retaining graft-versus-leukemia/lymphoma (GVL) responses. However, the mechanisms by which IL-21 may lead to a separation of GVHD and GVL remain incompletely understood. In a murine MHC-mismatched BM transplantation model, we observed that IL-21 receptor knockout (IL-21R KO) donor T cells mediate decreased systemic and gastrointestinal GVHD in recipients of a transplant. This reduction in GVHD was associated with expansion of transplanted donor regulatory T cells and with tissue-specific modulation of Th-cell function. IL-21R KO and wild-type donor T cells showed equivalent alloactivation, but IL-21R KO T cells showed decreased infiltration and inflammatory cytokine production within the mesenteric lymph nodes. However, Th-cell cytokine production was maintained peripherally, and IL-21R KO T cells mediated equivalent immunity against A20 and P815 hematopoietic tumors. In summary, abrogation of IL-21 signaling in donor T cells leads to tissue-specific modulation of immunity, such that gastrointestinal GVHD is reduced, but peripheral T-cell function and GVL capacity are retained. IL-21 is thus an exciting target for therapeutic intervention and improvement of clinical transplantation outcomes.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21596854 PMCID: PMC3138694 DOI: 10.1182/blood-2010-07-294785
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113